SpringerLink
Log in

Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

Androgen deprivation therapy (ADT) use in prostate cancer (PCa) has seen a rising trend. We are looking into the relationship between ADT and development of metabolic diseases in Chinese patients.

Methods

This is a prospective multi-centre cohort yielded from the READT database (Real-life experience of ADT in Asia), in which patients diagnosed of PCa and offered ADT were prospectively recruited since 2016. Chinese patients recruited from Hong Kong were selected and compared to another cohort of newly diagnosed PCa patients in Hong Kong (HK-Cap database), which was collected prospectively and retrieved retrospectively for this study. Patient outcomes are followed through for 2 years. We compared between the groups the new diagnoses of hypertension, diabetes and hyper-lipidaemia, as well as the initiation of related medication for these conditions. Baseline characteristics including pre-treatment comorbidities, medications and tumour characteristics are documented.

Results

151 patients receiving ADT (from READT database) and 447 patients not receiving ADT (from HK-Cap database) were analysed. ADT is related to higher risks of develo** any of concerned medical co-morbidities (23.8% vs 13.0*, p = 0.001) and new-onset DM (16.6% vs 4.4%, p < 0.001). Initiation of new medications is also more common in ADT patients. New anti-hypertensives (37.8% vs 12.5%, p < 0.001), oral hypoglycemic agents (12.6% vs 4.9%, p = 0.001), insulin (4.0% vs 0.05%, p = 0.001) and statin (23.7% vs 12.8%, p = 0.023) are more commonly added in ADT cohort.

Conclusion

Chinese receiving ADT are exposed to increased risks of new-onset hypertension, diabetes and hyper-lipidaemia, and a higher likelihood of step** up pharmaceutical control for pre-existing comorbidities. This highlights physicians’ role to monitor metabolic profiles in at-risk men upon offering ADT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T et al (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2):467–479. https://doi.org/10.1016/j.eururo.2013.11.002

    Article  CAS  PubMed  Google Scholar 

  2. Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R et al (2011) Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 378(9809):2104–2111. https://doi.org/10.1016/s0140-6736(11)61095-7

    Article  PubMed  PubMed Central  Google Scholar 

  3. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA et al (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87(2):599–603. https://doi.org/10.1210/jcem.87.2.8299

    Article  CAS  PubMed  Google Scholar 

  4. Damodaran S, Kyriakopoulos CE, Jarrard DF (2017) Newly diagnosed metastatic prostate cancer: has the paradigm changed? Urol Clin North Am 44(4):611–621. https://doi.org/10.1016/j.ucl.2017.07.008

    Article  PubMed  PubMed Central  Google Scholar 

  5. Aapro MS (2012) Management of advanced prostate cancer in senior adults: the new landscape. Oncologist 17(Suppl 1):16–22. https://doi.org/10.1634/theoncologist.2012-s1-16

    Article  PubMed  PubMed Central  Google Scholar 

  6. Shore ND, Antonarakis ES, Cookson MS, Crawford ED, Morgans AK, Albala DM et al (2020) Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. Prostate 80(6):527–544. https://doi.org/10.1002/pros.23967

    Article  PubMed  PubMed Central  Google Scholar 

  7. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD et al (2001) The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86(9):4261–4267. https://doi.org/10.1210/jcem.86.9.7851

    Article  CAS  PubMed  Google Scholar 

  8. Hellerstedt BA, Pienta KJ (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52(3):154–179. https://doi.org/10.3322/canjclin.52.3.154

    Article  PubMed  Google Scholar 

  9. Lage MJ, Barber BL, Markus RA (2007) Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology 70(6):1104–1108. https://doi.org/10.1016/j.urology.2007.08.012

    Article  CAS  PubMed  Google Scholar 

  10. Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF, Suissa S (2011) Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol 60(6):1244–1250. https://doi.org/10.1016/j.eururo.2011.08.041

    Article  CAS  PubMed  Google Scholar 

  11. Yu IC, Lin HY, Sparks JD, Yeh S, Chang C (2014) Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome. Diabetes 63(10):3180–3188. https://doi.org/10.2337/db13-1505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. McGrowder DA, Jackson LA, Crawford TV (2012) Prostate cancer and metabolic syndrome: is there a link? Asian Pac J Cancer Prev 13(1):1–13. https://doi.org/10.7314/APJCP.2012.13.1.001

    Article  PubMed  Google Scholar 

  13. Teoh JY, Chiu PK, Chan SY, Poon DM, Cheung HY, Hou SS et al (2015) Risk of new-onset diabetes after androgen deprivation therapy for prostate cancer in the Asian population. J Diabetes 7(5):672–680. https://doi.org/10.1111/1753-0407.12226

    Article  CAS  PubMed  Google Scholar 

  14. Teoh JY, Chiu PK, Chan SY, Poon DM, Cheung HY, Hou SS et al (2015) Risk of ischemic stroke after androgen deprivation therapy for prostate cancer in the Chinese population living in Hong Kong. Jpn J Clin Oncol 45(5):483–487. https://doi.org/10.1093/jjco/hyv025

    Article  PubMed  Google Scholar 

  15. Teoh JY, Chan SY, Chiu PK, Poon DM, Cheung HY, Hou SS et al (2015) Risk of acute myocardial infarction after androgen-deprivation therapy for prostate cancer in a Chinese population. BJU Int 116(3):382–387. https://doi.org/10.1111/bju.12967

    Article  CAS  PubMed  Google Scholar 

  16. Akaza H (2010) Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment. Pharmacology 85(2):110–120. https://doi.org/10.1159/000274486

    Article  CAS  PubMed  Google Scholar 

  17. Shim M, Bang WJ, Oh CY, Lee YS, Jeon SS, Ahn H et al (2020) The use of gonadotropin-releasing hormone agonist does not affect the development of cardiovascular disease in prostate cancer patients: a nationwide population-based cohort study. J Korean Med Sci 35(4):e47. https://doi.org/10.3346/jkms.2020.35.e47

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kiwata JL, Dorff TB, Schroeder ET, Gross ME, Dieli-Conwright CM (2016) A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients. Prostate Cancer Prostatic Dis 19(4):323–332. https://doi.org/10.1038/pcan.2016.25

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Taylor LG, Canfield SE, Du XL (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115(11):2388–2399. https://doi.org/10.1002/cncr.24283

    Article  PubMed  Google Scholar 

  20. Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M et al (2004) Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 89(1):61–70. https://doi.org/10.1210/jc.2003-030313

    Article  CAS  PubMed  Google Scholar 

  21. Faris JE, Smith MR (2010) Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes 17(3):240–246. https://doi.org/10.1097/med.0b013e3283391fd1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S et al (1996) Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334(15):952–957. https://doi.org/10.1056/nejm199604113341504

    Article  CAS  PubMed  Google Scholar 

  23. Ng CF, Chiu PKF, Yee CH, Lau BSY, Leung SCH, Teoh JYC (2020) Effect of androgen deprivation therapy on cardiovascular function in Chinese patients with advanced prostate cancer: a prospective cohort study. Sci Rep 10(1):18060. https://doi.org/10.1038/s41598-020-75139-w

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Hu JR, Duncan MS, Morgans AK, Brown JD, Meijers WC, Freiberg MS et al (2020) Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. Arterioscler Thromb Vasc Biol 40(3):e55–e64. https://doi.org/10.1161/atvbaha.119.313046

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Haque R, UlcickasYood M, Xu X, Cassidy-Bushrow AE, Tsai HT, Keating NL et al (2017) Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. Br J Cancer 117(8):1233–1240. https://doi.org/10.1038/bjc.2017.280

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Martin-Merino E, Johansson S, Morris T, Garcia Rodriguez LA (2011) Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care. Drug Saf 34(11):1061–1077. https://doi.org/10.2165/11594540-000000000-00000

    Article  PubMed  Google Scholar 

  27. Seong JM, Shin D, Sung JW, Cho S, Yang J, Kang S et al (2020) Gonadotropin-releasing hormone agonists, anti-androgens and the risk of cardio-cerebrovascular disease in prostate cancer patients: an asian population-based observational study. J Cancer 11(14):4015–4022. https://doi.org/10.7150/jca.38237

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Wang LH, Liu CK, Chen CH, Kao LT, Lin HC, Huang CY (2016) No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men. Andrology 4(1):128–132. https://doi.org/10.1111/andr.12141

    Article  CAS  PubMed  Google Scholar 

  29. Smith MR, Lee H, Nathan DM (2006) Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91(4):1305–1308. https://doi.org/10.1210/jc.2005-2507

    Article  CAS  PubMed  Google Scholar 

  30. Lubart E, Yarovoy A, Gal G, Krakover R, Leibovitz A (2015) QT interval length in elderly prostatic cancer patients on anti-testosterone treatment. Isr Med Assoc J 17(6):356–359

    PubMed  Google Scholar 

  31. van Noord C, Rodenburg EM, Stricker BH (2011) Invited commentary: sex-steroid hormones and QT-interval duration. Am J Epidemiol 174(4):412–415. https://doi.org/10.1093/aje/kwr170

    Article  PubMed  Google Scholar 

  32. Moreira RB, Debiasi M, Francini E, Nuzzo PV, Velasco G, Maluf FC et al (2017) Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget 8(48):84572–84578. https://doi.org/10.18632/oncotarget.20028

    Article  PubMed  PubMed Central  Google Scholar 

  33. Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D et al (2018) The Cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer 16(3):e645–e653. https://doi.org/10.1016/j.clgc.2017.12.007

    Article  PubMed  Google Scholar 

  34. Amit U, Lawrence YR, Weiss I et al (2019) Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer? Radiat Oncol 14:99. https://doi.org/10.1186/s13014-019-1298-9

    Article  PubMed  PubMed Central  Google Scholar 

  35. Ross RW, **e W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK (2008) Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 112(6):1247–1253. https://doi.org/10.1002/cncr.23304

    Article  PubMed  Google Scholar 

  36. Palumbo C, Antonelli A, Triggiani L, Dalla Volta A, Maffezzoni F, Zamboni S et al (2021) Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study. Prostate Cancer Prostatic Dis 24(3):852–859. https://doi.org/10.1038/s41391-021-00345-0

    Article  CAS  PubMed  Google Scholar 

  37. Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J (2014) Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65(3):565–573. https://doi.org/10.1016/j.eururo.2013.10.032

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China

    Chris Wong, Jeremy Teoh, Peter Chiu, C. H. Yee, Helen Wan, Steven Leung & C. F. Ng

  2. Division of Urology, Department of Surgery, Alice Ho Miu Ling Nethersole Hospital, Tai Po, Hong Kong, China

    C. F. Ng

  3. Urology Division, Department of Surgery, Tuen Mun Hospital, Tuen Mun, Hong Kong, China

    Peggy Chu, Lysander Chau & Marco Chan

  4. Urology Division, Department of Surgery, Pok Oi Hospital, Yuen Long, Hong Kong, China

    Peggy Chu, Lysander Chau & Marco Chan

  5. Division of Urology, Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China

    Chris Wong, Jeremy Teoh, Peter Chiu, C. H. Yee & C. F. Ng

  6. Division of Urology, Department of Surgery, North District Hospital, Sheung Shui, Hong Kong, China

    C. F. Ng

Authors
  1. Chris Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peggy Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeremy Teoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Chiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. H. Yee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lysander Chau
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marco Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Helen Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Steven Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C. F. Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. F. Ng.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wong, C., Chu, P., Teoh, J. et al. Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study. Int Urol Nephrol 54, 993–1000 (2022). https://doi.org/10.1007/s11255-022-03151-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-022-03151-2

Keywords

Search

Navigation